PUBLISHER: The Business Research Company | PRODUCT CODE: 1955451
PUBLISHER: The Business Research Company | PRODUCT CODE: 1955451
Huntington's disease treatment consists of medical therapies aimed at managing the symptoms of this progressive neurological disorder. The primary objectives are to slow disease progression, relieve symptoms, and improve the patient's quality of life.
The main types of Huntington's disease treatment include symptomatic treatments and disease-modifying therapies. Symptomatic treatments focus on easing symptoms and enhancing quality of life without targeting the underlying cause, and are increasingly sought after to help patients manage daily challenges. These therapies can be administered orally, intravenously, subcutaneously, or topically for applications in genetic, neurological, and psychiatric disorders. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by hospitals, clinics, home care settings, research institutions, and other healthcare facilities.
Tariffs have affected the huntington's disease treatment market by increasing the cost of imported active pharmaceutical ingredients, biologic components, and advanced therapy manufacturing inputs used in neurological drugs. These impacts have been most pronounced in disease-modifying and gene therapy segments, particularly in North America and Europe where cross-border clinical development and API sourcing are common. Asia-Pacific manufacturers have faced pricing pressures due to trade dependencies on specialized raw materials. However, tariffs have encouraged localized production and regional clinical manufacturing, supporting long-term supply resilience.
The huntington's disease treatment market research report is one of a series of new reports from The Business Research Company that provides huntington's disease treatment market statistics, including huntington's disease treatment industry global market size, regional shares, competitors with a huntington's disease treatment market share, detailed huntington's disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the huntington's disease treatment industry. This huntington's disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The huntington's disease treatment market size has grown rapidly in recent years. It will grow from $0.82 billion in 2025 to $0.92 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to limited treatment options for neurodegenerative disorders, increasing diagnosis of genetic neurological diseases, early reliance on symptomatic management, expansion of neurology specialty care, growth in hospital-based neurological treatments.
The huntington's disease treatment market size is expected to see rapid growth in the next few years. It will grow to $1.48 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to advancements in gene therapy technologies, rising investment in rare disease research, increasing orphan drug designations, growing precision medicine adoption, expanding pipeline of disease-modifying therapies. Major trends in the forecast period include growing focus on disease-modifying therapies, increasing adoption of gene and RNA-based treatments, expansion of combination therapy approaches, rising emphasis on symptom-specific drug development, increasing clinical trial activity for rare neurological disorders.
The rising adoption of gene therapies is expected to drive the growth of the Huntington's disease treatment market in the coming years. Gene therapies are treatments that modify or replace defective genes to prevent or cure diseases at the genetic level. Their growth is fueled by advances in precision medicine, which allow for the direct targeting of genetic causes and improved outcomes compared to traditional treatments. In Huntington's disease, gene therapies work by silencing the defective HTT gene that produces harmful proteins, thereby preventing nerve cell damage. This approach helps slow disease progression, preserve brain function, and offers potential for long-term disease management. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drug and device data, reported that the number of gene therapies in phase II increased from 247 at the end of Q1 2023 to 260 by the end of Q2, reflecting a 5% growth. Consequently, the expansion of gene therapies is propelling the Huntington's disease treatment market.
Leading companies in the Huntington's disease treatment market are focusing on developing advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, to potentially enhance patient quality of life while slowing disease progression. Selective VMAT2 inhibitor capsules are drugs that block the vesicular monoamine transporter 2, a protein responsible for packaging neurotransmitters for release in the brain. By reducing neurotransmitter release, these medications help manage involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules to treat chorea associated with Huntington's disease (HD) in adults. These once-daily oral VMAT2 inhibitor capsules work by decreasing excessive dopamine signaling in the brain to help control involuntary movements. They are available in multiple strengths and can be taken with or without food, providing patients with a convenient dosing option.
In December 2024, PTC Therapeutics Inc., a US-based pharmaceutical company developing treatments for Huntington's disease, partnered with Novartis AG to advance a Huntington's disease therapy. This collaboration is intended to accelerate the development and global commercialization of PTC518, a potential first-in-class oral, disease-modifying treatment for Huntington's disease. Novartis AG is a Switzerland-based manufacturer of drugs for Huntington's disease.
Major companies operating in the huntington's disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy's Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.
North America was the largest region in the Huntington's disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington's disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the huntington's disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The Huntington's disease treatment market consists of sales of products including tetrabenazine, deutetrabenazine, huntingtin-lowering therapies, cannabinoids, and cognitive enhancers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Huntington's Disease Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses huntington's disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for huntington's disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The huntington's disease treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.